Oxcarbazepine (All indications)

Neonatal medical care

id	Study   Auto Aydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020Bank (Oxcarbazepine) (Mixed indications), 2017Artama (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2013Artama (Oxcarbazepine) (Controls unexposed, disease free), 2013Artama (Oxcarbazepine) (Controls unexposed, sick), 2013Viinikainen (Oxcarbazepine) (Controls unexposed, disease free) a, 2006	Lib. in paper	Exposition period  Auto during pregnancy (anytime or not specified)1st trimester2nd trimester3rd trimester2nd and/or 3rd trimesterthroughout pregnancyearly pregnancydays before deliverylate pregnancypreconception-onlypericonceptionalpreconceptional for kinetic reasonat least 1st trimester3 months (or more) before pregnancy or during pregnancy1st and 2nd trimester3 months or more before pregnancy or1st trimester	Study type  All studies Case control excluded Only case control	Control type    Auto unexposed (general population or NOS)unexposed, sickunexposed, disease freeexposed to other treatment, sicknot specifiedwhatever (meta-analysis)	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S9039 R30842	Aydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020	Neonatal intensive care unit (NICU)	throughout pregnancy	retrospective cohort	exposed to other treatment, sick excluded	Adjustment: No	0.83 [0.05;13.63] C excluded (control group)	1/4   2/7	3	4		ref
S9040 R30852	Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020	Neonatal intensive care unit (NICU)	throughout pregnancy	retrospective cohort	unexposed, sick	Adjustment: No	3.33 [0.23;49.10] C	1/4   2/22	3	4		ref
S9042 R30869	Bank (Oxcarbazepine) (Mixed indications), 2017	Admission to neonatal intensive care unit (NICU) or Special Care Nursery	during pregnancy (anytime or not specified)	prospective cohort	exposed to other treatment, sick	Adjustment: No	0.65 [0.03;14.14] C	0/4   6/36	6	4		ref
S9036 R30803	Artama (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2013	Admission to neonatal care unit	3rd trimester	population based cohort retrospective	exposed to other treatment, sick excluded	Adjustment: No	0.59 [0.35;1.01] C excluded (control group)	46/465   24/154	70	465		ref
S9037 R30815	Artama (Oxcarbazepine) (Controls unexposed, disease free), 2013	Admission to neonatal care unit	3rd trimester	population based cohort retrospective	unexposed, disease free excluded	Adjustment: Yes	1.33 [0.98;1.82] excluded (control group)	46/465   49,612/689,482	49,658	465		ref
S9038 R30827	Artama (Oxcarbazepine) (Controls unexposed, sick), 2013	Admission to neonatal care unit	3rd trimester	population based cohort retrospective	unexposed, sick	Adjustment: Yes	1.04 [0.73;1.49]	46/465   152/1,708	198	465		ref
S9064 R30943	Viinikainen (Oxcarbazepine) (Controls unexposed, disease free) a, 2006	Admission to a neonatal unit	throughout pregnancy	prospective cohort	unexposed, disease free	Adjustment: No	37.81 [1.54;928.50] C	2/2   1,822/24,778	1,824	2		ref
					Total	4 studies	2.02 [0.48;8.47]		2,031	475
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

Sensitivity analysis

Publication bias and p-hacking diagnosis

Sub-groups analysis using all included studies

excluded 9036, 9037, 9039